Lori Muffly, MD
Hematology · Stanford, CANPI 1427256254
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $56,021 of the $86,597 with a category attached, or 64.7%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.3%.
Across 85 payments — averaging $1018.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$18K
- Adaptive Biotechnologies Corporation$16K
- Pfizer$13K
- Incyte Corporation$10K
- National Marrow Donor Program$6K
- Amgen$6K
- plus $17K from 9 others
Across 78 payments — averaging $26,194 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1.5M
- Astellas Pharma Global Development$199K
- Adaptive Biotechnologies Corporation$166K
- Servier Affaires Medicales$88K
- National Marrow Donor Program$27K
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- plus $29K from 3 others
What the payments were for
- Consulting fees$56,02165%
- Speaking & faculty fees$21,51825%
- Travel & lodging$4,3475%
- Food & beverage$4,5835%
- Gifts$1300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 12 | $18,467 |
| Adaptive Biotechnologies Corporation | 17 | $16,443 |
| Pfizer | 6 | $12,572 |
| Incyte Corporation | 6 | $10,136 |
| National Marrow Donor Program | 19 | $6,436 |
| Amgen | 6 | $5,984 |
| Astellas Pharma Global Development | 5 | $5,890 |
| Autolus Inc | 2 | $5,775 |
| Jazz Pharmaceuticals Inc. | 2 | $2,200 |
| Medexus Pharma, Inc. | 1 | $2,040 |
| Bristol Myers Squibb | 3 | $350 |
| Novartis | 2 | $153 |
| Merck | 2 | $81 |
| Johnson & Johnson | 1 | $44 |
| CSL Behring | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,597 in reported general payments places this provider in the 80th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 111 | $1,345,867 |
| RezurockBelumosudil Mesylate | 24 | $453,277 |
| Posaconazole | 16 | $16,391 |
| Acyclovir | 106 | $2,367 |
| Tacrolimus | 11 | $734 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 37 | $290 |
| Prednisone | 20 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $10,136 | $1,345,867111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 178 hematology providers in California.
Other hematology in Stanford
- Everett MeyerStanford$2.1M
- Deepu MadduriStanford$348K
- Surbhi SidanaStanford$170K
- Michaela LiedtkeStanford$112K
- Sydney LuStanford$110K
- Saurabh DahiyaStanford$94K
- David MiklosStanford$90K
- Ravindra MajetiStanford$58K
- Robert NegrinStanford$38K
- Rondeep BrarStanford$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.